ClinicalTrials.gg

Program

aflibercept

Also written as “Aflibercept”, “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” and “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”.

Its studies are mostly in Macular Degeneration · Macular Edema · Colorectal Neoplasms · Lymphoma, Non-Hodgkin · Retinal Vein Occlusion, led by 15 companies.

Furthest: phase 4, since Nov 2, 201286 company-led studies, 5 open or runningNext primary completion: Jul 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals251 open or runningphase 4since Nov 2, 2012May 13, 2002none ahead
Bayer230 open or runningphase 4since Apr 10, 2014Mar 12, 2008none ahead
Sanofi200 open or runningphase 3since May 16, 2006Jan 30, 2006none ahead
Novartis40 open or runningphase 4since Jul 22, 2016Jul 22, 2016none ahead
Amgen31 open or runningphase 3since Feb 13, 2020Feb 13, 2020Jul 31, 2027phase 3 · NCT07614776
Sam Chun Dang Pharm.20 open or runningphase 3since Jul 17, 2020Jul 17, 2020none ahead
AbbVie11 open or runningphase 2since Mar 16, 2022Mar 16, 2022Jun 2031phase 2 · NCT05296447
AO GENERIUM11 open or runningphase 3since Sep 18, 2026Sep 18, 2026May 2028phase 3 · NCT07844148
bioeq-gmbh10 open or runningphase 3since Aug 11, 2020Aug 11, 2020none ahead
cinnagen10 open or runningphase 3since Sep 18, 2022Sep 18, 2022none ahead
Exegenesis Bio11 open or runningphase 1since Jan 30, 2025Jan 30, 2025Feb 2029phase 1 · NCT06817343
formycon-ag10 open or runningphase 4since Nov 25, 2024Nov 25, 2024none ahead
Qilu Pharmaceutical10 open or runningphase 3since Apr 19, 2022Apr 19, 2022none ahead
Samsung Bioepis10 open or runningphase 2since Sep 21, 2026Sep 21, 2026none ahead
the-emmes-company-llc10 open or runningphase 3since Oct 22, 2013Oct 22, 2013none ahead

Also a collaborator on its studies: regenxbio-inc and parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Jul 10, 2009.

  1. Aug 19, 2022Phase 4 study in Diabetic Macular EdemaBayer · NCT05511038 · 100 enrolled · India
  2. Sep 18, 2022cinnagen's first study: phase 3 study in Macular DegenerationNew to cinnagencinnagen · NCT05587062 · 168 enrolled · Iran, Islamic Republic of
  3. Jan 20, 2023Phase 3 study in Chorioretinal Vascular DiseaseAmgen · NCT05704725 · 49 enrolled · United States
  4. Apr 28, 2023Phase 3 study in Macular Edema Secondary to Retinal Vein OcclusionBayer · NCT05850520 · 892 enrolled · United States, Australia, Austria and more
  5. Aug 3, 2023Phase 3 study in Diabetic Macular Edema (DME)Regeneron Pharmaceuticals · NCT05989126 · 35 enrolled · United States
  6. May 15, 2024Phase 3 study in Diabetic Macular EdemaBayer · NCT06422507 · 333 enrolled · China, Hong Kong
  7. Jul 1, 2024Phase 3 study in Neovascular Age-Related Macular DegenerationRegeneron Pharmaceuticals · NCT06491914 · 1,126 enrolled · United States, Puerto Rico
  8. Sep 8, 2024Phase 4 study in Diabetic Macular EdemaBayer · NCT06591598 · 51 enrolled · Czechia, Hungary, Slovakia
  9. Nov 25, 2024formycon-ag's first study: phase 4 study in Macular DegenerationNew to formycon-agformycon-ag · NCT06708637 · 30 enrolled · United States
  10. Jan 30, 2025Exegenesis Bio's first study: phase 1 study in Macular DegenerationNew to Exegenesis BioExegenesis Bio · NCT06817343 · 12 enrolled · United States
  11. Mar 24, 2026Phase 2 study in Macular DegenerationSam Chun Dang Pharm. · NCT07501052 · 33 enrolled · United States
  12. May 22, 2026Phase 3 study in Neovascular Age-related Macular DegenerationAmgen · NCT07614776 · 304 planned · United States, Czechia, Hungary and more
  13. Sep 18, 2026AO GENERIUM's first study: phase 3 study in nAMDNew to AO GENERIUMAO GENERIUM · NCT07844148 · 180 planned · Russia
  14. Sep 21, 2026Samsung Bioepis's first study: phase 2 study in Neovascular Age-related Macular DegenerationNew to Samsung BioepisSamsung Bioepis · NCT07844343 · 33 enrolled · South Korea

Ahead

  1. Jul 31, 2027Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationAmgen · NCT07614776
  2. May 2028Primary completion: phase 3 study in nAMDAO GENERIUM · NCT07844148
  3. Feb 2029Primary completion: phase 1 study in Macular DegenerationExegenesis Bio · NCT06817343
  4. Jun 2031Primary completion: phase 2 study in Diabetic RetinopathyAbbVie · NCT05296447

TargetBeta

PGF →VEGFA →read by rule
“Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor”ChEMBL 37, by rule

Studies

The newest 60 of 86 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07844343Neovascular Age-related Macular Degeneration · South Korea2CompletedSamsung BioepisSep 22, 202633
NCT07844148nAMD · Russia3RecruitingAO GENERIUMMay 2028180
NCT07614776Neovascular Age-related Macular Degeneration · United States, Czechia, Hungary and more3RecruitingAmgenJul 31, 2027304
NCT07501052Macular Degeneration · United States2CompletedSam Chun Dang Pharm.May 27, 202633
NCT06817343Macular Degeneration · United States1Active, not recruitingExegenesis BioFeb 202912
NCT06708637Macular Degeneration · United States4Completedformycon-agOct 8, 202430
NCT06591598Diabetic Macular Edema · Czechia, Hungary, Slovakia4CompletedBayerOct 14, 202551
NCT06491914Neovascular Age-Related Macular Degeneration · United States, Puerto Rico3Active, not recruitingRegeneron PharmaceuticalsAug 26, 20251,126
NCT06422507Diabetic Macular Edema · China, Hong Kong3CompletedBayerDec 29, 2025333
NCT05989126Diabetic Macular Edema (DME) · United States3CompletedRegeneron PharmaceuticalsMay 31, 202435
NCT05850520Macular Edema Secondary to Retinal Vein Occlusion · United States, Australia, Austria and more3CompletedBayerNov 7, 2024892
NCT05704725Chorioretinal Vascular Disease · United States3CompletedAmgenFeb 17, 202349
NCT05587062Macular Degeneration · Iran, Islamic Republic of3CompletedcinnagenJul 31, 2022168
NCT05511038Diabetic Macular Edema · India4CompletedBayerApr 16, 2024100
NCT05473715Macular Degeneration · Canada, United Kingdom4TerminatedBayerJul 11, 20233
NCT05345236Wet Age-related Macular Degeneration · China3CompletedQilu PharmaceuticalJan 25, 2022366
NCT05296447Diabetic Retinopathy · United States2Active, not recruitingAbbVieJun 2031103
NCT05282004Neovascular Age-related Macular Degeneration (nAMD) · United States3CompletedNovartisSep 7, 202236
NCT05161806Neovascular Age-related Macular Degeneration (nAMD) · United States3CompletedNovartisMay 4, 202230
NCT04864834Neovascular Age-related Macular Degeneration · United States, Australia, Austria and more3CompletedNovartisJul 7, 2022485
NCT04522167Neovascular Age-related Macular Degeneration · Bulgaria, Czechia, Hungary and more3Completedbioeq-gmbhJun 23, 2022434
NCT04480463Macular Degeneration · United States, Australia, Bulgaria and more3CompletedSam Chun Dang Pharm.Sep 8, 2022576
NCT04429503Diabetes Mellitus, Type 1 · United States, Canada, Czechia and more3CompletedRegeneron PharmaceuticalsMay 30, 2022660
NCT04270747Macular Degeneration · United States, Canada, Czechia and more3CompletedAmgenJul 18, 2022576
NCT04126317Macular Degeneration · United States, Puerto Rico2CompletedRegeneron PharmaceuticalsMay 14, 2021106
NCT04101721Retinopathy of Prematurity · United States, Bulgaria, Colombia and more3CompletedRegeneron PharmaceuticalsAug 18, 2022127
NCT04015180Retinopathy of Prematurity · Argentina, Belgium, Brazil and more3CompletedBayerSep 19, 2025100
NCT04004208Retinopathy of Prematurity · Argentina, Austria, Belgium and more3CompletedBayerFeb 12, 2021113
NCT03767738Chorioretinal Vascular Disease · United States4CompletedRegeneron PharmaceuticalsAug 19, 202065
NCT03639675Glaucoma, Neovascular · Japan3CompletedBayerFeb 14, 201916
NCT02878681Visual Impairment Due to Diabetic Macular Edema4WithdrawnNovartisSep 20170
NCT02818998Macular Edema · Austria, Canada, Czechia and more3CompletedBayerNov 13, 2018463
NCT02800642Retinal Vein Occlusion · Australia, Canada, Denmark and more4CompletedBayerJul 31, 2019162
NCT02718326Nonproliferative Diabetic Retinopathy · United States, Germany, Hungary and more3CompletedRegeneron PharmaceuticalsAug 6, 2018402
NCT02712008Diabetic Macular Edema · United States2CompletedRegeneron PharmaceuticalsJul 10, 2017302
NCT02581995Macular Edema · Austria, Canada, Czechia and more4CompletedBayerAug 9, 2017560
NCT02581891Macular Degeneration · Australia, Canada, France and more4CompletedBayerApr 26, 2019287
NCT02540954Macular Degeneration · Austria, Canada, Czechia and more3CompletedBayerDec 24, 2019336
NCT02418754Neovascular Age-Related Macular Degeneration · United States, Japan2TerminatedRegeneron PharmaceuticalsAug 17, 2016505
NCT02396316Glaucoma, Neovascular · Japan3CompletedBayerJun 16, 201654
NCT02305238Wet Macular Degeneration · Japan4CompletedBayerDec 22, 2016288
NCT02120950Neovascular Macular Degeneration · Australia, Germany, Hong Kong and more4CompletedBayerAug 12, 2016333
NCT01969708Retinal Vein Occlusion · United States3Completedthe-emmes-company-llcNov 2016362
NCT01955629Colorectal Cancer Metastatic · Italy2TerminatedSanofiMar 20154
NCT01882868Colorectal Cancer Metastatic · Japan2CompletedSanofiAug 201562
NCT01783886Macular Edema · China, Hong Kong, Korea, Republic of and more3CompletedBayerMar 2015381
NCT01722045Macular Degeneration · United States4CompletedRegeneron PharmaceuticalsSep 2015154
NCT01661270Colorectal Cancer Metastatic · China, Hong Kong, Japan and more3CompletedSanofiOct 2014332
NCT01670721Colorectal Cancer Metastatic · France3CompletedSanofiJun 2015175
NCT01571284Colorectal Cancer Metastatic · United States, Belgium, Brazil and more3CompletedSanofiJan 31, 2017781
NCT01521559Retinal Vein Occlusion · United States, Canada, Japan3CompletedRegeneron PharmaceuticalsAug 2013183
NCT01512966Macular Edema · Japan3CompletedBayerSep 201373
NCT01482910Macular Degeneration · China3CompletedBayerMar 2014304
NCT01363440Diabetic Retinopathy · United States3CompletedRegeneron PharmaceuticalsJan 2013466
NCT01331681Diabetes Mellitus · Australia, Austria, Czechia and more3CompletedBayerJun 3, 2013406
NCT01249664Myopia, Degenerative · Hong Kong, Japan, Korea, Republic of and more3CompletedBayerFeb 2013122
NCT01148615Neoplasms · China1CompletedSanofiSep 201120
NCT01012973Retinal Vein Occlusion · Australia, Austria, France and more3CompletedBayerFeb 2011177
NCT00964795Macular Degeneration · United States, Canada3CompletedRegeneron PharmaceuticalsAug 2013323
NCT00943072Macular Edema · United States, Canada, Colombia and more3CompletedRegeneron PharmaceuticalsOct 2010189

How it is read

Names in the registry

  • “Aflibercept”, 9 entries
  • “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)”, 8 entries
  • “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”, 8 entries
  • “aflibercept”, 7 entries
  • “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)”, 7 entries

Codes read as this program: BAY865321, SCD411.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.